Home › NDC Lookup › RxCUI directory › RxCUI 1297761

Esomeprazole 5 MG Granules for Oral Suspension — RxCUI 1297761

RxNorm drug concept · Semantic clinical drug
RxCUI 1297761 Semantic clinical drug · SCD ● Current RxNorm concept 16 FDA products 18 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1297761
Official nameEsomeprazole 5 MG Granules for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asesomeprazole 5 MG (equivalent to esomeprazole magnesium 5.6 MG) Granules for Delayed Release Oral Suspension; esomeprazole 5 MG Granules for Delayed Release Oral Suspension
FDA products mapped16
Package NDCs mapped18
Reported Medicaid activity (SDUD)116,177 prescriptions · 41 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Esomeprazole Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It is used for erosive esophagitis from GERD when taking esomeprazole by mouth isn't possible or appropriate. It is also used in adults to lower the risk of bleeding again from sto...
  • Why am I getting esomeprazole through an IV?
  • For GERD, it is given for up to 10 days, and you switch to an oral form as soon as you can. For bleeding ulcers, the IV course lasts about 72 hours, and then you take an oral acid...
  • The most common are headache, gas, nausea, stomach pain, diarrhea, dry mouth, dizziness and irritation at the IV site. Let your nurse know if the IV site is painful, red or swollen...
📖 Read our full Esomeprazole Injection guide →

🕸️ Concept Web — How Esomeprazole 5 MG Granules for Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Esomeprazole 5 MG Granules for Oral Suspension RxCUI 1297761

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Esomeprazole 283742
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Nexium 284799
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Esomeprazole Granules for Oral Suspension 1855312
    • Esomeprazole Granule Product 1855311
    • Esomeprazole Oral Product 1165149
    • Esomeprazole Granules for Oral Suspension [Nexium] 1855315
    • Nexium Granule Product 1855316
    • Nexium Oral Product 1182869
    • Granules for Oral Suspension 1540454
    • Granule Product 1294708
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Esomeprazole 5 MG SCDC · 1855362
  • Esomeprazole Granules for Oral Suspension SCDF · 1855312
  • Esomeprazole Granule Product SCDG · 1855311
  • Esomeprazole Oral Product SCDG · 1165149

Brand-Name Concepts

  • Esomeprazole 5 MG Granules for Oral Suspension [Nexium] SBD · 1297763
  • Esomeprazole 5 MG [Nexium] SBDC · 1855364
  • Esomeprazole Granules for Oral Suspension [Nexium] SBDF · 1855315
  • Nexium Granule Product SBDG · 1855316
  • Nexium Oral Product SBDG · 1182869
  • Nexium BN · 284799

📦 FDA Products & Package NDCs

16 products · 18 package NDCs
18 package NDCs map to RxCUI 1297761 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00186-4010-01 30 GRANULE, DELAYED RELEASE in 1 CARTON (0186-4010-01) NEXIUM AstraZeneca Pharmaceuticals LP 2008-07-07
00186-4020-01 30 GRANULE, DELAYED RELEASE in 1 CARTON (0186-4020-01) NEXIUM AstraZeneca Pharmaceuticals LP 2007-03-19
00186-4025-01 30 GRANULE, DELAYED RELEASE in 1 CARTON (0186-4025-01) NEXIUM AstraZeneca Pharmaceuticals LP 2012-09-05
00186-4040-01 30 GRANULE, DELAYED RELEASE in 1 CARTON (0186-4040-01) NEXIUM AstraZeneca Pharmaceuticals LP 2007-03-19
00186-4050-01 30 GRANULE, DELAYED RELEASE in 1 CARTON (0186-4050-01) NEXIUM AstraZeneca Pharmaceuticals LP 2012-09-05
00186-5020-31 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0186-5020-31) NEXIUM AstraZeneca Pharmaceuticals LP 2001-03-19
00186-5020-54 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0186-5020-54) NEXIUM AstraZeneca Pharmaceuticals LP 2001-03-19
00186-5040-31 30 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0186-5040-31) NEXIUM AstraZeneca Pharmaceuticals LP 2001-03-19
00186-5040-54 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE (0186-5040-54) NEXIUM AstraZeneca Pharmaceuticals LP 2001-03-19
13668-0546-94 30 GRANULE, DELAYED RELEASE in 1 CARTON (13668-546-94) Esomeprazole Magnesium for delayed-release oral suspension Torrent Pharmaceuticals Limited 2025-03-05
13668-0547-94 30 GRANULE, DELAYED RELEASE in 1 CARTON (13668-547-94) Esomeprazole Magnesium for delayed-release oral suspension Torrent Pharmaceuticals Limited 2025-03-05
13668-0549-94 30 GRANULE, DELAYED RELEASE in 1 CARTON (13668-549-94) Esomeprazole Magnesium for delayed-release oral suspension Torrent Pharmaceuticals Limited 2025-03-05
13668-0550-94 30 GRANULE, DELAYED RELEASE in 1 CARTON (13668-550-94) Esomeprazole Magnesium for delayed-release oral suspension Torrent Pharmaceuticals Limited 2025-03-05
59651-0802-30 30 GRANULE, DELAYED RELEASE in 1 CARTON (59651-802-30) Esomeprazole Magnesium Aurobindo Pharma Limited 2025-04-15
59651-0804-30 30 GRANULE, DELAYED RELEASE in 1 CARTON (59651-804-30) Esomeprazole Magnesium Aurobindo Pharma Limited 2025-04-15
59651-0805-30 30 GRANULE, DELAYED RELEASE in 1 CARTON (59651-805-30) Esomeprazole Magnesium Aurobindo Pharma Limited 2025-04-15
69097-0507-31 30 FOR SUSPENSION in 1 CARTON (69097-507-31) Esomeprazole magnesium Cipla USA Inc. 2025-01-07
69097-0508-31 30 FOR SUSPENSION in 1 CARTON (69097-508-31) Esomeprazole magnesium Cipla USA Inc. 2025-01-07
Observed labelers: AstraZeneca Pharmaceuticals LP (9) · Torrent Pharmaceuticals Limited (4) · Aurobindo Pharma Limited (3) · Cipla USA Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.